Hexahydrocannabinol

Hexahydrocannabinol
Clinical data
ATC code
  • None
Legal status
Legal status
Identifiers
  • (6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,9,10,10a-hexahydrobenzo[c]chromen-1-ol
CAS Number
  • 6692-85-9 946512-74-9 (6aR,10aR) (unspecified stereochemistry)
PubChem CID
ChemSpider
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC21H32O2
Molar mass316.485 g·mol−1
3D model (JSmol)
  • CCCCCC1=CC(=C2[C@@H]3CC(CC[C@H]3C(OC2=C1)(C)C)C)O
  • InChI=1S/C21H32O2/c1-5-6-7-8-15-12-18(22)20-16-11-14(2)9-10-17(16)21(3,4)23-19(20)13-15/h12-14,16-17,22H,5-11H2,1-4H3/t14?,16-,17-/m1/s1
  • Key:XKRHRBJLCLXSGE-VNCLPFQGSA-N

Hexahydrocannabinol (HHC) is a phytocannabinoid that has been reported as a minor component of Cannabis oleoresin. It can also be synthesized by hydrogenation of a mixture of various tetrahydrocannabinol (THC) isomers, usually derived from hemp CBD isolate.

The synthesis and bioactivity of HHC was first reported in 1940 by Roger Adams.

HHC is a psychoactive substance with effects reportedly similar to those of THC. HHC vaporizers have been openly sold at head shops and convenience stores since at least the early 2020s in North America and Europe. While HHC has never been approved by any drug regulatory agency, a racemic mixture of epimers has shown in vitro activity against pancreatic ductal adenocarcinoma cell lines.